Brief: Innovent Biologics Says Jaypirca (Pirtrobrutinib) Approved In China For Cll/Sll Across All Lines Of Therapy
28/09/2026 13:09
BRIEF-Innovent Biologics Says Jaypirca (Pirtrobrutinib) Approved In China For Cll/Sll Across All Lines Of Therapy Sept 28 (Reuters) - Innovent Biologics, Inc. 1801.HK:
JAYPIRCA (PIRTROBRUTINIB) APPROVED IN CHINA FOR CLL/SLL ACROSS ALL LINES OF THERAPY
Further company coverage: 1801.HK
((reuters.briefs@thomsonreuters.com))
Recent news on Innovent Biologics
See all newsAdvisory: Alert on Innovent Biologics Phase 3 study results withdrawn
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals